Table 1.
Patient characteristics and treatments
| Characteristic | GBM | Grade III | Total |
|---|---|---|---|
| Sex | |||
| Female | 7 (70) | 3 (30) | 10 |
| Male | 6 (40) | 9 (60) | 15 |
| Median age (range, yr) | 50 (43-75) | 42 (23-81) | - |
| MGMT promoter methylation status | |||
| Methylated | 3 (42.9) | 4 (57.1) | 7 |
| Unmethylated | 2 (66.7) | 1 (33.3) | 3 |
| Unknown | 8 (53.3) | 7 (46.7) | 15 |
| IDH mutation | |||
| Present | 1 (33.3) | 2 (66.7) | 3 |
| Absent | 2 (66.7) | 1 (33.3) | 3 |
| Unknown | 10 (52.6) | 9 (47.4) | 19 |
| 1p19q codeletion status | |||
| Codeleted | NA | 3 | 3 |
| Non-codeleted | NA | NA | - |
| Unknown | NA | NA | - |
| Time to relapse from initial diagnosis (mo) | |||
| ≤ 12 | 7 (70) | 3 (30) | 10 |
| 12-24 | 3 (50) | 3 (50) | 6 |
| > 24 | 3 (33.3) | 6 (66.7) | 9 |
| Treatment at initial diagnosis | |||
| Surgery | |||
| Complete resection | 9 (60) | 6 (40) | 15 |
| Subtotal resection | 1 (100) | 0 (0) | 1 |
| Partial resection | 1 (14.3) | 6 (85.7) | 7 |
| Biopsy | 2 (100) | 0 | 2 |
| Radiotherapy | 13 (52) | 12 (48) | 25 |
| CT concomitant and adjuvant (TMZ) | 13 (52) | 12 (48) | 25 |
Values are presented as number (%). GBM, glioblastoma; MGMT, methylguanine-DNA methyltransferase; IDH, isocitrate dehydrogenase; NA, not acquired; CT, chemotherapy; TMZ, temozolomide.